Abstract | BACKGROUND: AIM: To evaluate whether rifaximin was associated with the risk of death and cirrhotic complications. METHODS: RESULTS: In the non-HCC cohort, 145 patients received rifaximin plus lactulose (the rifaximin group) and 276 patients received lactulose alone (the control group). The multivariate analysis revealed that rifaximin was significantly associated with lower risk of death (adjusted hazard ratio [aHR], 0.697; P = .024) and reduced the risk of recurrent HE (aHR, 0.452; P < .001), SBP (aHR, 0.210; P < .001) and variceal bleeding (aHR, 0.425; P = .011) but not HRS (aHR, 0.598; P = .08). In the HCC cohort, 173 patients received rifaximin plus lactulose and 448 patients received lactulose. Rifaximin was not associated with the risk of death (aHR, 1.177; P = .121). Rifaximin was associated with lower risk of SBP (aHR, 0.323; P < .001) but not with variceal bleeding (aHR, 0.660; P = .104) or recurrent HE (aHR, 0.689; P = .057). The risk of Clostridium difficile-associated diarrhoea was not different between the groups (aHR, 0.028; P = .338). CONCLUSIONS:
|
Authors | S H Kang, Y B Lee, J-H Lee, J Y Nam, Y Chang, H Cho, J-J Yoo, Y Y Cho, E J Cho, S J Yu, M Y Kim, Y J Kim, S K Baik, J-H Yoon |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 46
Issue 9
Pg. 845-855
(11 2017)
ISSN: 1365-2036 [Electronic] England |
PMID | 28836723
(Publication Type: Journal Article)
|
Copyright | © 2017 John Wiley & Sons Ltd. |
Chemical References |
- Anti-Infective Agents
- Rifamycins
- Lactulose
- Rifaximin
|
Topics |
- Aged
- Anti-Infective Agents
(therapeutic use)
- Bacterial Infections
(prevention & control)
- Carcinoma, Hepatocellular
(drug therapy)
- Esophageal and Gastric Varices
(prevention & control)
- Female
- Hepatic Encephalopathy
(complications, drug therapy)
- Humans
- Lactulose
(therapeutic use)
- Liver Cirrhosis
(etiology)
- Liver Neoplasms
(drug therapy)
- Male
- Middle Aged
- Peritonitis
(prevention & control)
- Recurrence
- Retrospective Studies
- Rifamycins
(therapeutic use)
- Rifaximin
- Secondary Prevention
|